Premium
Detecting recurrence of macular edema in patients with wet AMD after anti‐VEGF treatment using 3D‐CTAG test
Author(s) -
MILYUTKINA S,
FINK W,
KOVALEVSKAYA M
Publication year - 2014
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2014.f067.x
Subject(s) - medicine , ophthalmology , macular edema , ranibizumab , edema , blind spot , contrast (vision) , surgery , retinal , bevacizumab , chemotherapy , artificial intelligence , computer science
Purpose To detect recurrence of macular edema inwet AMD patients after anti‐VEGF treatment using 3D‐Computer‐automated Threshold Amsler Grid testing (3D‐CTAG; Fink &Sadun, 2004). Methods Wet AMD patients (n=10, 11 eyes) 6 months after 3 injections of Ranibizumab (Lucentis, Novartis). Group #1(n=5, 6 eyes): norecurrence. Group #2 (n=5, 5 eyes): recurrence confirmed by OCT. Indices: # of VF defects per eye (ND); lowest perceivable contrast level (CL); VF volume lost relative to hill‐of‐vision (VLRH); lost area grade (LAG): [scotoma area at lowest tested contrast sensitivity level/scotoma area at highest tested contrast sensitivity level]×scotoma depth (%). Results Group #1:Visus=0,43±0,18logMAR; ND=0,67±1,2; CL=10±7,04%; VLRH=2,1±3,97%; LAG=150,92±341,35%. Group #2:Visus=0,51±0,49logMAR; ND=1,4±0,55; CL=38,8±12,03%; VLRH=15,18±10,56%; LAG=32,13±20,13%. Conclusion In group #2 3D‐CTAG revealed scotomas typical for macular edema: VLRH=15,18±10,56% compared to 2,1±3,97% (p=0,05) in group #1 and LAG=32,13±20,13% compared to 150,92±341,35% (p=0,05) in group #1. Observed functional disorders show that 3‐fold injection of Ranibizumab, adopted as the standard, appears to be insufficient in 45,45% of the cases. 3D‐CTAG may be an effective method for self‐monitoring the recurrence of macular edema in wet AMD patients.Commercial interest